GKOS

Glaukos Corp.'s stock price has increased significantly by 63.24% over the past six months. Strong financial results, including record net sales for Q3 2025, Q4 2025, and Q1 2026, and raised 2026 net sales guidance have positively impacted the stock. FDA approval and commercialization of iDose TR and Epioxa have also been significant catalysts. Analyst sentiment is optimistic, with a "Moderate Buy" to "Strong Buy" rating. As of May 1, 2026, the stock price was $140.22, up from $112.80 on January 1, 2026, and is near its 52-week high of $146.75.